Lecithin:cholesterol acyltransferase (LCAT) is the sole enzyme that esterifies cholesterol in plasma. Its role in the supposed protection from atherogenesis remains unclear because mutations in LCAT causing fish-eye disease (FED) or familial LCAT deficiency (FLD) have been reported to be associated with more or instead less carotid atherosclerosis, respectively. This discrepancy may be associated with the loss of cholesterol esterification on only apolipoprotein AI (FED) or on both apolipoprotein AI-and apolipoprotein Bcontaining lipoproteins (FLD), an aspect that has thus far not been investigated.
G
enetic lecithin:cholesterol acyltransferase (LCAT) deficiency is a rare autosomal recessive disorder caused by mutations in the LCAT gene.
1 These mutations translate into 2 different clinical presentations known as familial LCAT deficiency (FLD; Online Mendelian Inheritance in Man No. 245900) and fisheye disease (FED; Online Mendelian Inheritance in Man No. 136120). Compound heterozygosity or homozygosity for mutations causing either FLD or FED is characterized by near-absent high-density lipoprotein (HDL) cholesterol. 2 Furthermore, heterozygosity for mutations in LCAT causes up to a 40% decrease in HDL cholesterol. 3, 4 In individuals with FLD, the lack of LCAT catalytic activity is complete, thereby affecting the ability of the enzyme to esterify free cholesterol on both HDL and low-density lipoprotein (LDL). As a consequence, cholesteryl esters are virtually absent in plasma. In contrast, mutations causing FED result in a loss of the capacity of LCAT to esterify cholesterol only in HDL yet retain the ability to esterify cholesterol on apolipoprotein B-containing lipoproteins (very-low-density lipoprotein and LDL). As a result, plasma cholesteryl esters are associated mainly with LDL particles. 2 Clinical manifestations of a loss of LCAT activity are observed only in subjects who are homozygotes or compound heterozygotes for LCAT mutations. 2 Corneal opacity is the most common feature in individuals with FLD and FED, whereas anemia, proteinuria, and renal disease are clinical features in only those with FLD. 2 Of note, glomerulosclerosis is the major cause of morbidity and mortality in individuals with FLD because it ultimately leads to renal failure. 2 The pathogenesis of renal disease in FLD is not completely understood, but it is likely related to the accumulation of abnormal lipoproteins, including largemolecular-weight LDL particles 5 and lipoprotein X. 6 Epidemiological studies have clearly established the inverse association between HDL cholesterol and risk of cardiovascular disease (CVD). 7 Thus, individuals with nearly complete loss of HDL or even half the normal HDL are hypothesized to be at very high CVD risk. In a first study by Ayyobi et al, 8 however, 2 homozygotes and 7 heterozygotes from a large Canadian kindred with FLD were followed up for 25 years, during which time no vascular events were reported in any of the carriers up to 70 years of age. The homozygotes had only minimally greater carotid intima-media thickness (IMT) and no plaques, whereas some IMT abnormalities were observed in 4 of 7 heterozygotes. 8 In a much larger carotid IMT study in the Netherlands, measurements were performed in 9 carriers of 2 mutant LCAT alleles, 47 carriers of 1 mutant LCAT allele, and 58 ageand sex-matched family control subjects. All individuals belonged to 5 families in whom the index cases all presented with FED. 3 Heterozygous carriers were reported to have significantly greater carotid IMT compared with family control subjects, and 2 individuals had premature cardiovascular events. 3 This population was later reassessed by measuring carotid artery wall thickness by 3.0-T carotid magnetic resonance imaging showing that these carriers of LCAT mutations had thicker carotid artery walls and 32% more plaque component compared with family control subjects. 9 In sharp contrast, a study in Italian families in which the majority of the index cases had FLD showed significantly smaller carotid IMT in carriers of LCAT mutations compared with age-and sex-matched control subjects, with a convincing distinct gene-dose effect. 4 These contrasting prior findings suggest the following question: Does the development of preclinical atherosclerosis follow a different course in partial LCAT deficiency (FED) compared with complete LCAT deficiency (FLD)? It is critical that this question is addressed because the answer will influence the effectiveness and safety of pharmaceutical strategies that target LCAT. These include enzyme replacement therapy to treat
Clinical Perspective
What Is New?
• A half-century of lecithin:cholesterol acyltransferase (LCAT) research has established its important function in high-density lipoprotein metabolism; however, the role of this enzyme in human atherogenesis remains controversial.
• In this study, we tested the hypothesis that genetic mutations causing complete LCAT deficiency (familial LCAT deficiency) or partial LCAT deficiency (fish-eye disease) are differentially associated with carotid atherosclerosis in carriers of LCAT mutations.
• Using carotid intima-media thickness as a measure
of atherosclerosis, we demonstrate that carriers of LCAT mutations leading to familial LCAT deficiency exhibit less carotid atherosclerosis, indicating a reduced risk of cardiovascular disease.
• In contrast, carriers of LCAT mutations leading to fish-eye disease show marginally more atherosclerosis.
• The association of mutations in LCAT with subclinical atherosclerosis appears to be related to the capacity of LCAT to esterify cholesterol on apolipoprotein B-containing lipoproteins because the abnormal LCAT present in fish-eye disease is active only on this class of lipoproteins.
What Are the Clinical Implications?
• These findings bear relevance for pharmaceutical strategies that target LCAT such as the recombinant enzyme for replacement therapy and, more important, small molecules aimed at increasing LCAT activity that previously has been thought to decrease the risk of atherosclerosis.
ORIGINAL RESEARCH ARTICLE
FLD 10 and, more important, small molecules aimed at increasing LCAT activity to decrease the risk of atherosclerosis. 11 In this light, we have tested the hypothesis that FLD and FED are 2 disease entities with different associations with atherosclerosis. Our results highlight remarkable discrepancies between the 2 LCAT disease entities in the first head-to-head comparison.
METHODS
The raw data that support the findings of this study are available from the corresponding authors on reasonable request.
Subjects
A total of 375 subjects were included in this study, 168 recruited from Italy and 207 from the Netherlands. Among the 168 Italian subjects, 55 were carriers of LCAT mutations in previously identified families, 12, 13 and 113 were control subjects recruited among blood donors. From 207 Dutch subjects, 40 were carriers of LCAT mutations and 167 were control subjects (comprising 137 family members 9 and 30 age-and sex-matched healthy control subjects).
A total of 16 individuals were carriers of 2 mutant LCAT alleles (homozygotes or compound heterozygotes), 11 of whom were biochemically 12 diagnosed with FLD, all Italians, whereas 5 subjects (4 Italians and 1 Dutch) were classified as FED. Seventy-nine individuals carried 1 mutant LCAT allele and were assigned to either the FLD or FED group on the basis of all available data. Specifically, heterozygotes for mutations known to cause FLD or FED in homozygotes were assigned FLD or FED, respectively. In case such information was not present (in families in whom the index cases were compound heterozygotes), we used biochemical information that was obtained through in vitro characterization of the respective mutants. 4 If such information was not available, the subjects were excluded from our study, which was the case in 5 individuals. Thus, of the 74 remaining heterozygotes, 33 (26 Italians and 7 Dutch) and 41 (9 Italians and 32 Dutch) subjects were classified as FLD and FED, respectively. A detailed and complete overview of the LCAT mutations and associated biochemical phenotype can be found in the online-only Data Supplement, including mutation carriers who were not included because no appropriate data were present to assign them to either the FLD or FED group (Table I in the online-only Data Supplement).
Personal history and family history of CVD and cardiovascular risk factors were surveyed by questionnaires. Personal history and family history of CVD were not specifically used to include or exclude subjects for this study. Biometrics, including blood pressure, were recorded, and fasting blood samples were collected. Hypertension was defined as a blood pressure >140/90 mm Hg or the use of antihypertensive medication. None of the participants were taking medication known to affect plasma lipid/lipoprotein levels. All subjects were fully informed about the modalities of the study and signed informed consent. All procedures were approved by the institutional ethics committees.
Biochemical Analysis
Plasma total and HDL cholesterol and triglyceride levels were determined with certified enzymatic methods. In addition, LDL and non-HDL cholesterol were calculated by the Friedewald equation and as the difference between total and HDL cholesterol, respectively. In the case of triglycerides levels >400 mg/dL (2 carriers and 2 control subjects), LDL cholesterol was assessed with a direct measurement method.
Carotid Ultrasonography
Carotid IMT was performed with standardized techniques for all carriers of LCAT gene mutations and control subjects. All ultrasonographic scans were performed with the subjects lying in the supine position. Right and left carotid artery segments (common carotid artery, bifurcation, and internal carotid artery) were identified according to specific landmarks (ie, flow divider and crest of the bifurcation) and imaged over a 10-mm length according to a fixed lateral transducer angle (lateral). In both the Netherlands and Italy, the affected families are living across the 2 nations. All carriers and control subjects who agreed to participate in the Netherlands were asked to attend the Department of Vascular Medicine in Amsterdam for IMT assessment, whereas all carriers and control subjects who agreed to participate in Italy were asked to attend the Lipid Clinic of the Center E. Grossi Paoletti in Milan. In Italy, when carriers could not travel to Milan, the sonographer moved to the family's site.
In the Netherlands, an Acuson 128XP/10v equipped with a 7.0-MHz linear-array transducer was used to obtain B-mode ultrasound images of carotid arteries by 2 blinded sonographers. In Italy, ultrasound scanning was also performed by 2 blinded sonographers by using an ESAOTE TECHNOS machine equipped with a multifrequency probe of 8.5 MHz. When 1 of the 2 sonographers moved to the family's site around the country, ultrasound scanning was performed with a portable device (Logiq E compact ultrasound portable system; GE Healthcare) equipped with a 5.0-to 13.0-MHz linear-array transducer. In the Netherlands, images were saved as JPEG image files, whereas in Italy, the whole ultrasonographic scan was recorded on super VHS videotapes from 3 transducer angles (anterior, lateral, and posterior). To be congruent with Dutch ultrasonographic protocol, only images from the lateral angle were considered. All IMT measurements were centralized in Milan and performed by a single expert reader blinded to the genotype of the subjects who used dedicated software (M'Ath, Metris SRL France) that allows the semiautomatic edge detection of the echogenic lines of the intima-media complex. Whenever possible, carotid images were measured in at least 3 different frames. Measurements of left and right common carotids were averaged to calculate the mean common carotid IMT.
Measurements of the 3 segments (common carotid artery, bifurcation, and internal carotid artery) of the left and right carotids were averaged to calculate the mean IMT (average IMT). The highest IMT value among the 3 segments of the 2 carotids was defined as the maximum IMT.
Statistical Analysis
Data were summarized as mean±SD or as mean and 95% confidence interval for normally distributed variables, as median and interquartile range for nonnormally distributed variables, and as number (percent) for categorical variables. Carotid IMT variables were log-transformed before ORIGINAL RESEARCH ARTICLE multivariable analysis and were presented as geometric means and 95% confidence interval. Unadjusted pairwise comparisons between groups were performed by Wilcoxon rank-sum test, χ 2 test, or Fisher exact test as indicated. Multivariable analysis was performed by ANCOVA using 3 different models: model 1, adjusted for age and sex; model 2, same as model 1 with additional adjustment for body mass index, smoking, hypertension, family history of CVD, total cholesterol, HDL cholesterol, and triglycerides; and model 3, same as model 2 with further adjustments for nation and ultrasonographic machine. P values <0.05 were considered significant except when appropriate Bonferroni correction was applied. All tests were 2 sided and were performed by SAS version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS

Demographic Characteristics and Lipid Levels
Individuals from the previously reported Italian and Dutch families with mutations in LCAT were combined and analyzed following identical methods. For the current analysis, we excluded homozygotes and compound heterozygotes to account for possible referral bias because these patients may have initially been studied as a result of cardiovascular complications. The final cohort includes 74 proven heterozygous carriers of LCAT gene mutations (33 with FLD and 41 with FED) and 280 control subjects. Table 1 summarizes the demographic, lifestyle, and clinical characteristics of the subjects included. Statistical comparisons were made as individuals with FED versus those with FLD, subjects with FED versus control subjects, and those with FLD versus control subjects.
Age and sex distributions were very similar among all 3 study groups, and body mass index and hypertension were not significantly different between all groups. In addition, the FED and FLD groups were similar for smoking status. Personal history of CVD was significantly increased in those with FED compared with control subjects, whereas family history of CVD was comparable in the 3 groups.
With respect to lipids, total cholesterol was significantly lower in individuals with FLD and FED compared with control subjects (167.5±39.0 versus 200.4±38.5 mg/ dL in those with FLD versus control subjects, P<0.0001; 185.5±52.5 versus 200.4±38.5 mg/dL in those with FED 
Carotid IMT in FLD and FED Mutation Carriers
Carotid IMT values are presented using 3 different statistical adjustments: model 1, adjusted for age and sex; model 2, same as model 1 with additional adjustment for body mass index, smoking, hypertension, family history of CVD, total cholesterol, HDL cholesterol, and triglycerides; model 3, same as model 2 with further adjustments for nationality and ultrasonographic machine ( .001, respectively). In terms of average and maximum IMT, subjects with FED were not different from control subjects regardless of the statistical model used (Table 2) .
On inclusion of carriers of 2 mutant LCAT alleles (homozygotes/compound heterozygotes; Tables II and III in   Table 2 Data are geometric means (95% confidence interval). β Coefficients are computed on log-transformed variables. FED indicates fish-eye disease; FLD, familial lecithin:cholesterol acyltransferase deficiency; IMT, intima-media thickness; and LCAT, lecithin:cholesterol acyltransferase.
Model 1 was adjusted for age and sex; model 2 is the same as model 1 plus body mass index, smoking, hypertension, family history of cardiovascular disease, total cholesterol, high-density lipoprotein cholesterol, and triglycerides; and model 3 is the same as model 2 plus nationality and ultrasonographic machine. *P<0.006 (Bonferroni correction for 9 independent comparisons).
the online-only Data Supplement), the analysis yielded very similar results (Table IV in the online-only Data Supplement).
DISCUSSION
Despite 50 years of research, the role of LCAT in the pathogenesis of atherogenesis remains unclear. For example, opposite findings were reported by Hovingh et al 3 and Calabresi et al, 4 who described more and less carotid atherosclerosis in carriers of LCAT gene mutations, respectively. It is important to emphasize, however, that Hovingh et al 3 studied only families in whom the probands were diagnosed with FED, whereas Calabresi et al 4 almost exclusively investigated families in whom the probands had FLD. In the present study, we have carefully discriminated between these 2 LCAT disease entities on the basis of clinical and biochemical features. This was anticipated to be important because LCAT in FED can still esterify cholesterol on apolipoprotein B-containing lipoproteins, whereas such activity is missing in FLD.
After assigning carriers to FLD or FED groups, we first tested the hypothesis that mutations that are associated with FLD or FED have different impacts on the development of atherosclerosis. To this end, the previously described Dutch and Italian cohorts were combined and used to reread all carotid IMT images. The study groups and control subjects had a very similar cardiovascular risk profile. The result shows that mutations causing FLD and FED are indeed differentially associated with subclinical atherosclerosis as determined by IMT. Specifically, the FLD group presented with significantly lower IMT compared with control subjects among all 3 carotid measurements, thereby validating previous findings. 4 The FED group, however, showed a slight increase in only the common carotid IMT compared with control subjects, as reported earlier. 3 The latter was also in agreement with an additional report on carotid 3.0-T magnetic resonance imaging data in the same individuals. 9 In terms of our hypothesis, the FLD group showed significantly lower IMT values across all carotid segments compared with the FED group. To account for possible imbalances between the Italian and Dutch study sites, all IMT measurements were additionally adjusted for nationality and ultrasonographic machine; average and maximum IMT in subjects with FLD remained highly significantly lower compared with subjects with FED, which supports the validity of our findings.
Because the major cardiovascular risk factors were similar in the FLD and FED groups, the identified chang- In an attempt to explain the differences in atherosclerosis observed between subjects with familial lecithin:cholesterol acyltransferase (LCAT) deficiency (FLD) and fish-eye disease (FED), we depicted the relevant underlying biological mechanism(s). LCAT esterifies cholesterol on either high-density lipoprotein (HDL; α activity) or low-density lipoprotein (LDL; β activity). In carriers of LCAT mutations, the α activity (encoded by the FED allele) is compromised, but cholesteryl ester (CE) can still be generated on proatherogenic very-low-density lipoprotein (VLDL) through normal β activity (encoded by the mutant and wild-type LCAT allele; A). In contrast, the reduction of both α and β activity in carriers of FLD mutations has a larger effect on overall plasma CE and on atherogenic apolipoprotein B-containing lipoproteins compared with FED (B). FC indicates free cholesterol.
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es in IMT may be related to differences in plasma lipid fractions resulting from different functions in the mutant LCAT proteins. Notably, LDL cholesterol levels were 18% lower in subjects with FLD compared with those with FED. In view of the established causal role of LDL cholesterol in atherogenesis, this may explain the observed differences in subclinical atherosclerosis between the FLD and FED groups when considering the lifelong impact of this detrimental lipid feature. This was recently highlighted by studies of mutations in another gene in which a 28% reduction of LDL cholesterol observed in carriers of loss-of-function mutations in PCSK9 was shown to be associated with a remarkable 88% reduction of the risk of coronary heart disease. 14 Non-HDL cholesterol was also nonsignificantly reduced in subjects with FLD compared with those with FED and control subjects. Because the reduction of HDL cholesterol levels was similar in both the FLD and FED groups compared with control subjects, this parameter is unlikely to account for differences in IMT between the groups. We cannot exclude, however, that HDL subclasses or sizes of LDL and very-low-density lipoprotein particles are associated with our observations. 15 Placing our results in a broader perspective, others have shown that low LCAT activity and high pre-β1 HDL concentration are strong positive risk markers for ischemic heart disease but independent of HDL cholesterol. 16 We previously showed that LCAT concentration is not associated with HDL cholesterol levels or future coronary artery disease 17 and reported that a low plasma concentration and activity of LCAT are not associated with carotid atherosclerosis. 18 When we consider the relations between LCAT and HDL cholesterol, the above findings are not in line with those obtained in families with FLD and FED. This may be explained by relatively large reductions in LCAT activity in carriers of LCAT mutations, whereas the variation of LCAT concentrations in other studies was marginal by comparison. 17, 18 When we consider the relation between HDL cholesterol and CVD, the first report on a strong inverse association between HDL cholesterol and atherosclerosis 7, 19 has been confirmed by many other investigators. There is, however, little evidence from studies in humans that this relationship has a causal basis. 20 In terms of the role of LCAT in HDL metabolism, a recent mendelian randomization study showed that low HDL cholesterol associated with a common LCAT gene variation is not associated with an altered risk of myocardial infarction. 21 In line with the notion that this relationship may not be causal, the present study shows that a marked, assumedly lifelong 29% to 36% reduction in HDL cholesterol levels in carriers of LCAT mutations is not associated with a markedly greater carotid IMT. In fact, we recapitulate that carriers of FLD with very marked hypoalphalipoproteinemia surprisingly appear significantly protected against carotid atherosclerosis.
Taken together, our data show that carriers of FLD mutations exhibit less carotid atherosclerosis, whereas those with FED mutations present with slightly more atherosclerosis. We propose that this discrepancy is related to the capacity of LCAT to esterify cholesterol on apolipoprotein B-containing lipoproteins (Figure) . This is supported by significantly lower LDL cholesterol in carriers of FLD mutations compared with carriers of FED mutations. However, further studies are warranted to improve our insight into possible mechanisms underlying the observed differences in the 2 LCAT syndromes. Such studies, which we were not able to perform here, may encompass measures of lipoprotein composition and size and cholesterol esterification. In closing, we emphasize that our findings may bear consequences for therapeutic approaches to increase LCAT activity to fight atherosclerosis.
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